Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pantoprazole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Pantoprazole. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2020-005030-15 Sponsor Protocol Number: B1791094 Start Date*: 2021-10-15
    Sponsor Name:Pfizer Inc.
    Full Title: AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 ...
    Medical condition: Erosive Esophagitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) BE (Trial now transitioned) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001132-45 Sponsor Protocol Number: 3001B3-333-WW Start Date*: 2006-08-07
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INF...
    Medical condition: INFANTS AGED 1 THROUGH 11 MONTHS WITH PRESUMED GERD
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000492-33 Sponsor Protocol Number: BY1023/M3-904 Start Date*: 2004-09-06
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000493-32 Sponsor Protocol Number: BY1023/M3-906 Start Date*: 2004-08-17
    Sponsor Name:ALTANA Pharma AG
    Full Title: Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparis...
    Medical condition: Gastroesophageal reflux esophagitis
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000483-27 Sponsor Protocol Number: CCT38473 Start Date*: 2020-11-19
    Sponsor Name:St. Joseph’s Healthcare, McMaster University
    Full Title: Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis in ICU
    Medical condition: critical illness requiring mechanical ventilation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-001474-24 Sponsor Protocol Number: 3001B3–335-WW Start Date*: 2006-08-07
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
    Full Title: A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD
    Medical condition: INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002226-22 Sponsor Protocol Number: 2.0 Start Date*: 2019-04-30
    Sponsor Name:Medical University of Vienna
    Full Title: The Impact of Target Temperature Management on Drug Metabolism
    Medical condition: Patients after successful cardiopulmonary resuscitation who undergo target temperature management for 24h hours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001473-24 Sponsor Protocol Number: 3001B3-331-WW Start Date*: 2007-01-16
    Sponsor Name:Wyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.
    Full Title: A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANT...
    Medical condition: Clinical diagnosis of gastroesophagal reflux disease (GERD) in neonates and preterm infants
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002182-29 Sponsor Protocol Number: B1791089 Start Date*: 2016-06-09
    Sponsor Name:Pfizer Inc.
    Full Title: An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age...
    Medical condition: Gastroesophageal Reflux Disease (GERD)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) IT (Completed) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004534-40 Sponsor Protocol Number: 3001B3-329-WW Start Date*: 2007-03-06
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT-WITHDRAWAL STUDY OF THE EFFICACY AND SAFETY OF PANTOPRAZOLE SODIUM ENTERIC-COATED GRANULES IN INFANTS (1 THROUGH 11 MONTHS) WI...
    Medical condition: Treatment of gastroesophageal reflux disease (GERD) symptoms in infants 1 through 11 months
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) LV (Completed) DE (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001497-27 Sponsor Protocol Number: BY1023/M3-713 Start Date*: 2005-08-12
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of pantoprazole on sleep-related breathing disorders
    Medical condition: Sleep-related breathing disorders
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004856-11 Sponsor Protocol Number: BY1023/DE004 Start Date*: 2006-07-12
    Sponsor Name:ALTANA Pharma AG
    Full Title: Symptom reduction in hospitalized patients suffering from symptomatic non-erosive or erosive gastroesophageal reflux disease treated with pantoprazole 20 or 40 mg o.d. for 7 days
    Medical condition: Symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004806-25 Sponsor Protocol Number: BY1023/M3-339 Start Date*: 2005-04-25
    Sponsor Name:ALTANA Pharma AG
    Full Title: Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. ove...
    Medical condition: Gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-000711-10 Sponsor Protocol Number: BY1023/UK506 Start Date*: 2005-07-07
    Sponsor Name:ALTANA Pharma Ltd.
    Full Title: Determination of the performance characteristics of ReQuestTM in Practice in the stepped down management of GORD
    Medical condition: Gastro-oesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    5.0 10038263 llt
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003485-42 Sponsor Protocol Number: BY1023/M3-341 Start Date*: 2006-03-24
    Sponsor Name:ALTANA Pharma AG
    Full Title: Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks
    Medical condition: gastroesophageal reflux disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000603-32 Sponsor Protocol Number: NL3364409612 Start Date*: 2012-08-27
    Sponsor Name:Annadalstichting
    Full Title: Proton pump inhibitors in the prevention of iron reaccumulation in patients with hereditary hemochromatosis
    Medical condition: Hereditary hemochromatosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017229-20 Sponsor Protocol Number: KCT 27/2009 – PAN-STAR/PL Start Date*: 2010-06-24
    Sponsor Name:KRKA-POLSKA Sp. z o.o.
    Full Title: Efficacy and safety of PANtoprazole in the treatment and SympTom relief in patients with gAstRoesophageal reflux disease (GERD) – PAN-STAR
    Medical condition: gastroesophageal reflux disease (GERD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004248-39 Sponsor Protocol Number: PPI-microbiome Start Date*: 2018-01-04
    Sponsor Name:TARGID, KU Leuven
    Full Title: Effect of Proton Pump Inhibitors on the duodenal microbiome in healthy volunteers
    Medical condition: We will assess the effect of Proton Pump Inhibitors (PPI) on the duodenal, oral and fecal microbiota composition in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004355-23 Sponsor Protocol Number: PPI-microbiome-FD Start Date*: 2018-01-04
    Sponsor Name:TARGID, KU Leuven
    Full Title: Effect of Proton Pump Inhibitors on the duodenal microbiome in Functional Dyspepsia patients
    Medical condition: Functional Dyspepsia (FD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005340-39 Sponsor Protocol Number: S64807 Start Date*: 2021-02-01
    Sponsor Name:University Hospitals Leuven
    Full Title: Duodenal neuro-immune interactions and effects of proton pump inhibitors in functional dyspepsia
    Medical condition: Functional Dyspepsia (FD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:18:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA